Projected savings from biosimilars from 2021 to 2025 were $38.4 billion vs conditions as of quarter 4 of 2020 and were driven by new biosimilar entry. Savings were $124.5 billion under an upper-bound scenario.
Andrew Mulcahy, PhD, MPP
Advertisement
Articles by Andrew Mulcahy, PhD, MPP
Advertisement
Latest Updated Articles
- Projected US Savings From Biosimilars, 2021-2025
January 3rd 2022
Advertisement
Advertisement
Trending on AJMC
1
Judge Denies Preliminary Injunction in Medicaid Work Requirements Case
2
FDA Panel Backs 6 Peptides for Compounding
3
AHRQ Grant Freeze Halts Patient Safety Research Nationwide
4
FDA Advisory Panel Votes Against Approval of Deramiocel for DMD
5